A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
Clinical trial NCT03911713 · COMPLETED
Trial details
- NCT number
- NCT03911713
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-17
- Primary completion
- 2020-08-20
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.